H. Lundbeck AS (FRA:LDBA) Piotroski F-Score: 5 (As of Jul. 04, 2026) — 29% Below Median


FRA:LDBA H. Lundbeck AS FRA:LDBA
81 GF Score
Price €5.93
GF Value €6.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is H. Lundbeck AS Piotroski F-Score?

H. Lundbeck AS FRA:LDBA +3.13% 81 Piotroski F-Score is 5 as of Jul. 04, 2026, which is 29% below its 10-year median of 7.00. GuruFocus rates FRA:LDBA with a GF Score™ of 81/100 and a GF Value™ of €6.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, H. Lundbeck AS ranks better than 61.57% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

H. Lundbeck AS has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for H. Lundbeck AS's Piotroski F-Score or its related term are showing as below:

FRA:LDBA' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 7   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of H. Lundbeck AS was 9. The lowest was 3. And the median was 7.

H. Lundbeck AS  (FRA:LDBA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


H. Lundbeck AS Piotroski F-Score Related Terms


H. Lundbeck AS Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Piotroski F-Score Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 9.00 8.00 7.00 5.00

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 6.00 5.00 5.00

FRA:LDBA vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Piotroski F-Score falls into.


FRA:LDBA
81GF Score
H. Lundbeck AS FRA:LDBA
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 129.487 + 147.516 + -3.615 + 221.826 = €495 Mil.
Cash Flow from Operations was 218.359 + 308.028 + 123.312 + 80.141 = €730 Mil.
Revenue was 807.35 + 841.281 + 815.788 + 953.262 = €3,418 Mil.
Gross Profit was 661.108 + 727.931 + 649.23 + 779.2 = €2,817 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(7269.227 + 6943.909 + 7126.975 + 6969.478 + 6997.947) / 5 = €7061.5072 Mil.
Total Assets at the begining of this year (Mar25) was €7,269 Mil.
Long-Term Debt & Capital Lease Obligation was €1,452 Mil.
Total Current Assets was €1,692 Mil.
Total Current Liabilities was €1,203 Mil.
Net Income was 103.169 + 104.209 + 79.113 + 150.16 = €437 Mil.

Revenue was 730.621 + 767.419 + 742.991 + 835.936 = €3,077 Mil.
Gross Profit was 589.133 + 620.695 + 599.381 + 690.603 = €2,500 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(5076.51 + 5237.081 + 5299.779 + 7731.61 + 7269.227) / 5 = €6122.8414 Mil.
Total Assets at the begining of last year (Mar24) was €5,077 Mil.
Long-Term Debt & Capital Lease Obligation was €2,025 Mil.
Total Current Assets was €1,590 Mil.
Total Current Liabilities was €1,018 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

H. Lundbeck AS's current Net Income (TTM) was 495. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

H. Lundbeck AS's current Cash Flow from Operations (TTM) was 730. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=495.214/7269.227
=0.06812471

ROA (Last Year)=Net Income/Total Assets (Mar24)
=436.651/5076.51
=0.08601401

H. Lundbeck AS's return on assets of this year was 0.06812471. H. Lundbeck AS's return on assets of last year was 0.08601401. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

H. Lundbeck AS's current Net Income (TTM) was 495. H. Lundbeck AS's current Cash Flow from Operations (TTM) was 730. ==> 730 > 495 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1452.169/7061.5072
=0.20564576

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2025.017/6122.8414
=0.33073158

H. Lundbeck AS's gearing of this year was 0.20564576. H. Lundbeck AS's gearing of last year was 0.33073158. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1692.057/1202.916
=1.40662939

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1589.687/1017.737
=1.56198212

H. Lundbeck AS's current ratio of this year was 1.40662939. H. Lundbeck AS's current ratio of last year was 1.56198212. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

H. Lundbeck AS's number of shares in issue this year was 992.4. H. Lundbeck AS's number of shares in issue last year was 991.9. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2817.469/3417.681
=0.82438033

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2499.812/3076.967
=0.8124273

H. Lundbeck AS's gross margin of this year was 0.82438033. H. Lundbeck AS's gross margin of last year was 0.8124273. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3417.681/7269.227
=0.47015742

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=3076.967/5076.51
=0.60611857

H. Lundbeck AS's asset turnover of this year was 0.47015742. H. Lundbeck AS's asset turnover of last year was 0.60611857. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

H. Lundbeck AS has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
H. Lundbeck AS (FRA:LDBA) has a Piotroski F-Score of 5 as of Jul. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on H. Lundbeck AS and its competitors. This is 29% below median its historical median of 7.00. Over the past decade, H. Lundbeck AS's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, H. Lundbeck AS ranks #377 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.4%.
Is H. Lundbeck AS's Piotroski F-Score too high?
H. Lundbeck AS's current Piotroski F-Score of 5 is 29% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. H. Lundbeck AS's value of 5 is 0% at this industry median. Based on the distribution chart, H. Lundbeck AS ranks #377 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #377 out of 981 companies for Piotroski F-Score. This puts H. Lundbeck AS in the upper half of its industry. The industry median Piotroski F-Score is 5.00. H. Lundbeck AS's value of 5 is 0% at this benchmark. Historically, H. Lundbeck AS's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, H. Lundbeck AS has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current Piotroski F-Score is 5, which is 29% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.31, compared to a current price of €5.93 — trading 6.1% below its estimated fair value. The current Piotroski F-Score is 5, which is 29% below median its 10-year median of 7.00 and 0% at the Drug Manufacturers industry median of 5.00. H. Lundbeck AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current Piotroski F-Score is 5 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • Piotroski F-Score: 5 (29% below median its 10-year median of 7.00)
  • GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
  • GF Score™: 81/100 with 4 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#377 of 981)

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score

Get the complete analysis for FRA:LDBA

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.93
Price
€6.31
GF Value